NeueHealth, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEUE research report →
Range $7 – $7
Price Chart
About the company
Operating within the United States, NeueHealth, Inc. is a healthcare enterprise dedicated to delivering a diverse array of medical solutions to patients, care providers, and insurance entities. The company is structured into two primary divisions.
- CEO
- George Lawrence Mikan III
- IPO
- 2021
- Employees
- 986
- HQ
- Doral, FL, US
Get TickerSpark's AI analysis on NEUE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $60.94M
- P/E
- -0.30
- Fwd P/E
- 8.77
- PEG
- -0.00
- P/S
- 0.07
- P/B
- -0.13
- EV/EBITDA
- -2.80
- Div Yield
- 0.00%
- Gross Margin
- 20.77%
- Op Margin
- -11.47%
- Net Margin
- -14.38%
- ROE
- 34.61%
- ROIC
- 65.56%
Latest fiscal year · YoY change
- Revenue
- $936.66M-19.3%
- Gross Profit
- $194.52M+18.4%
- Op Income
- $-107,410,000
- Net Income
- $-134,680,000+88.3%
- EPS
- $-22.65+85.0%
- OCF Growth
- +95.5%
- FCF Growth
- +95.4%
- 52W High
- $7.66
- 52W Low
- $3.79
- 50D MA
- $6.70
- 200D MA
- $6.74
- Beta
- 0.60
- RSI (14)
- 53
- Avg Volume
- 6.47K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NeueHealth delivered another profitable quarter, with adjusted EBITDA positive for the sixth straight quarter and consumer growth up about 45% year over year.· August 7, 2025
- Adjusted EBITDA was $19 million in Q2 and $32.5 million for the first half of 2025, marking the sixth consecutive profitable quarter.
- Q2 revenue was $209.1 million, slightly below last year due to a shift in membership mix away from ACO REACH.
- The company served 694,000 consumers in Q2, about 45% higher than Q2 2024.
- ACA Marketplace consumers reached 485,000, Medicare-related consumers were 65,000, and Medicaid consumers were 144,000 at quarter-end.
- Management highlighted growth in clinics, Walgreens site openings, and continued investment in the NeuePulse value-based care platform.
NeueHealth consolidated revenue was $209.1 million in the second quarter, slightly lower than the prior year due to a shift in membership mix away from ACO REACH. Second quarter gross margin was $62.7 million, and adjusted EBITDA was $19 million, the sixth consecutive quarter of profitability. The company served 694,000 consumers in Q2, up approximately 45% year over year. In NeueCare, revenue was $91.6 million and operating income was $23.2 million; in NeueSolutions, revenue was $120 million and operating income was $2.6 million. Cash and investments totaled $234.4 million as of June 30, 2025, including $145.5 million of nonregulated cash and short-term investments, of which $38.2 million was restricted. No quarterly or full-year guidance was given on the call.
Mike Mikan framed the quarter as evidence that the company’s focused, value-based model is working, emphasizing strong execution, disciplined profitable growth, and consumer-centric care. He highlighted 45% aggregate consumer growth, improved medical loss ratio performance in ACA Marketplace, expansion into Walgreens clinic locations, and the rollout of NeuePulse as a future core platform. His tone was upbeat and confident, including repeated references to the company’s momentum and being well positioned for the second half of the year.
Jay Matushak focused on the financial performance by segment and the balance sheet. He cited Q2 revenue of $209.1 million, gross margin of $62.7 million, adjusted EBITDA of $19 million, and first-half adjusted EBITDA of $32.5 million, along with segment revenue and operating income of $91.6 million and $23.2 million for NeueCare and $120 million and $2.6 million for NeueSolutions. On liquidity, he said total cash and investments were $234.4 million at June 30, 2025, including $145.5 million of nonregulated cash and short-term investments and $38.2 million of restricted cash and investments.
There was no analyst Q&A in the transcript, so no management responses to external questions were provided. The call was a prepared remarks-only update, with management emphasizing operating momentum, consumer growth, and the continued transition toward value-based care. The only notable forward-looking item mentioned was the previously announced go-private transaction, expected to close in mid to late 2025 pending closing conditions.
The bullish case is that NeueHealth is already producing sustained adjusted EBITDA profitability while still growing consumers rapidly, with Q2 up about 45% year over year. Management also pointed to improving ACA Marketplace economics, expanding clinic presence through partnerships like Walgreens, and a new platform, NeuePulse, that could deepen operational leverage and support future growth.
The main caution is that Q2 revenue was slightly lower year over year because of a shift in membership mix away from ACO REACH, showing the business is still sensitive to product mix changes. The company also did not provide quarterly or full-year guidance, and the planned go-private transaction remains subject to closing conditions. More broadly, much of the strategic story depends on continued execution in value-based care and the success of newer initiatives like NeuePulse.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 33.3%
- Shares Outstanding
- 9.02M
- Float Shares
- 3.01M
of shares held by institutions
39 13F filers
Buy/sell ratio 0.85. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 78.65K | ▲ 6.04K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 2, 25 | Matushak Jay | sell | 40,431 |
| Oct 2, 25 | Matushak Jay | sell | 6,340 |
| Oct 2, 25 | Bessemer Venture Partners IX L.P. | sell | 999,218 |
| Oct 2, 25 | Bessemer Venture Partners IX L.P. | sell | 8,500 |
| Oct 2, 25 | Kraus Stephen | sell | 0 |
| Oct 2, 25 | Kraus Stephen | sell | 0 |
| Oct 2, 25 | Craig Jeffery Michael | sell | 100,000 |
| Oct 2, 25 | Craig Jeffery Michael | sell | 20,103 |
| Oct 2, 25 | Orozco Tomas | sell | 48,000 |
| Oct 2, 25 | Orozco Tomas | sell | 29,325 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NEUE coverage
Recent articles, reports, and earnings notes.
No research on NEUE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NEUE report →NeueHealth Announces Closing of Take-Private Transaction
businesswire.com · Oct 2
NeueHealth, Inc. (NEUE) Q2 2025 Earnings Call Transcript
seekingalpha.com · Aug 8
Transcript : NeueHealth, Inc., Q2 2025 Earnings Call, Aug 07, 2025
https://www.marketscreener.com · Aug 7
NeueHealth Reports Second Quarter 2025 Results
businesswire.com · Aug 7
NeueHealth to Host Second Quarter 2025 Earnings Conference Call on August 7, 2025
businesswire.com · Jul 17
NeueHealth, Inc (NEUE) Q1 2025 Earnings Call Transcript
seekingalpha.com · May 11
NeueHealth Reports First Quarter 2025 Results
businesswire.com · May 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.